OraSure Launches HEMAcollect PROTEIN Blood Collection Tube for Proteomic Research.
PorAinvest
jueves, 10 de julio de 2025, 7:09 am ET1 min de lectura
OSUR--
The HEMAcollect●PROTEIN BCT is powered by ProteoPrecision™ technology, which minimizes hemolysis and platelet activation, ensuring the sample accurately reflects the body's state at the time of collection. This innovation addresses the limitations of general blood collection tubes, which often require refrigeration and have shorter stabilization periods [1].
The device is compatible with a broad range of proteomic technologies, including mass spectrometry, immunoassays, and high-throughput affinity-based platforms. This versatility makes it suitable for various research applications, such as oncology, neurology, cardiology, and metabolic disorders [1].
OraSure Technologies anticipates that the HEMAcollect●PROTEIN BCT will deliver operational and financial efficiencies for proteomic researchers. The ability to store and transport samples at ambient temperature simplifies workflows and reduces the need for specialized refrigeration equipment [1].
The launch of the HEMAcollect●PROTEIN BCT is part of OraSure Technologies' commitment to enhancing the quality of insights for researchers through innovative sample management solutions [1].
References:
[1] https://www.globenewswire.com/news-release/2025/07/10/3113127/11732/en/OraSure-Launches-Novel-Blood-Collection-Device-for-Proteomic-Research.html
OraSure Technologies has launched HEMAcollect●PROTEIN, an evacuated blood collection tube designed to preserve and stabilize plasma proteins in whole blood for up to seven days. The product is intended for research use only and is expected to provide operational and financial efficiencies for proteomic researchers while supporting the generation of high-quality data. The HEMAcollect●PROTEIN BCT can be stored and transported at ambient temperature, addressing limitations of general blood collection tubes.
OraSure Technologies, Inc. (NASDAQ: OSUR) has introduced a novel blood collection device, HEMAcollect●PROTEIN, designed to address the challenges faced by proteomic researchers. The device, developed by the company's subsidiary DNA Genotek, is an evacuated blood collection tube (BCT) that can preserve and stabilize plasma proteins in whole blood for up to seven days at ambient temperature [1].The HEMAcollect●PROTEIN BCT is powered by ProteoPrecision™ technology, which minimizes hemolysis and platelet activation, ensuring the sample accurately reflects the body's state at the time of collection. This innovation addresses the limitations of general blood collection tubes, which often require refrigeration and have shorter stabilization periods [1].
The device is compatible with a broad range of proteomic technologies, including mass spectrometry, immunoassays, and high-throughput affinity-based platforms. This versatility makes it suitable for various research applications, such as oncology, neurology, cardiology, and metabolic disorders [1].
OraSure Technologies anticipates that the HEMAcollect●PROTEIN BCT will deliver operational and financial efficiencies for proteomic researchers. The ability to store and transport samples at ambient temperature simplifies workflows and reduces the need for specialized refrigeration equipment [1].
The launch of the HEMAcollect●PROTEIN BCT is part of OraSure Technologies' commitment to enhancing the quality of insights for researchers through innovative sample management solutions [1].
References:
[1] https://www.globenewswire.com/news-release/2025/07/10/3113127/11732/en/OraSure-Launches-Novel-Blood-Collection-Device-for-Proteomic-Research.html
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios